Atria Investments Inc Has $217,000 Position in Alphatec Holdings, Inc. (NASDAQ:ATEC)

Atria Investments Inc raised its holdings in Alphatec Holdings, Inc. (NASDAQ:ATEC) by 20.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 23,585 shares of the medical technology company’s stock after acquiring an additional 3,976 shares during the quarter. Atria Investments Inc’s holdings in Alphatec were worth $217,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Charles Schwab Investment Management Inc. boosted its position in shares of Alphatec by 2.8% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 846,224 shares of the medical technology company’s stock worth $7,768,000 after purchasing an additional 23,002 shares during the last quarter. Oppenheimer Asset Management Inc. acquired a new position in Alphatec in the fourth quarter valued at about $106,000. Bank of New York Mellon Corp boosted its holdings in Alphatec by 119.3% during the fourth quarter. Bank of New York Mellon Corp now owns 662,239 shares of the medical technology company’s stock worth $6,079,000 after buying an additional 360,258 shares during the last quarter. Olympiad Research LP acquired a new position in shares of Alphatec during the 4th quarter worth about $160,000. Finally, Ieq Capital LLC bought a new stake in shares of Alphatec in the 4th quarter valued at about $323,000. Institutional investors and hedge funds own 66.35% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the stock. Needham & Company LLC restated a “buy” rating and set a $16.00 price objective on shares of Alphatec in a report on Thursday, February 27th. Piper Sandler boosted their price target on shares of Alphatec from $12.00 to $13.00 and gave the company an “overweight” rating in a report on Thursday, February 27th. StockNews.com upgraded shares of Alphatec from a “sell” rating to a “hold” rating in a research report on Friday, February 28th. Barclays lifted their target price on Alphatec from $20.00 to $21.00 and gave the stock an “overweight” rating in a report on Wednesday, January 22nd. Finally, HC Wainwright restated a “buy” rating and issued a $20.00 price target on shares of Alphatec in a report on Tuesday, January 14th. Two research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $17.67.

Alphatec Stock Performance

ATEC opened at $9.34 on Wednesday. The company has a market capitalization of $1.35 billion, a price-to-earnings ratio of -7.30 and a beta of 1.39. The business’s 50-day moving average price is $10.95 and its two-hundred day moving average price is $8.80. Alphatec Holdings, Inc. has a 1 year low of $4.88 and a 1 year high of $14.88. The company has a debt-to-equity ratio of 30.21, a current ratio of 2.32 and a quick ratio of 1.15.

Alphatec (NASDAQ:ATEC) last announced its earnings results on Wednesday, February 26th. The medical technology company reported ($0.23) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.04). Alphatec had a negative net margin of 31.06% and a negative return on equity of 541.39%. The firm had revenue of $176.79 million during the quarter, compared to analyst estimates of $172.74 million. Equities analysts expect that Alphatec Holdings, Inc. will post -1.08 EPS for the current fiscal year.

Insider Activity

In other news, COO Scott Lish sold 27,453 shares of the company’s stock in a transaction that occurred on Thursday, February 6th. The stock was sold at an average price of $11.49, for a total transaction of $315,434.97. Following the sale, the chief operating officer now owns 867,677 shares in the company, valued at $9,969,608.73. This represents a 3.07 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, EVP David Sponsel sold 58,283 shares of the firm’s stock in a transaction on Monday, January 13th. The shares were sold at an average price of $10.71, for a total transaction of $624,210.93. Following the completion of the transaction, the executive vice president now directly owns 502,311 shares of the company’s stock, valued at $5,379,750.81. This represents a 10.40 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 337,321 shares of company stock worth $3,828,060 over the last ninety days. Insiders own 22.80% of the company’s stock.

Alphatec Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.